|

Autologous, engineered T Cells targeting TP53 R175H Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • AstraZeneca1

Indications

  • Other Solid Tumors1
  • Colorectal Carcinoma1
  • Head and Neck Squamous Cell Carcinoma1
  • Pancreatic Adenocarcinoma1
  • Ovarian Cancer1

Gilbert, Arizona1 trial

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Research Site

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.